Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-03-02

FDA Approved: PIRFENIDONE — Supplemental Application (Accord Healthcare Inc.)

View source ↗

Summary

The FDA approved Accord Healthcare Inc.'s supplemental application to market a generic pirfenidone product for idiopathic pulmonary fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PIRFENIDONE (pirfenidone)

Snippet

SUPPL AP for PIRFENIDONE (PIRFENIDONE)